Novel small molecule α9α10 nicotinic receptor antagonist prevents and reverses chemotherapy-evoked neuropathic pain in rats

Anesthesia and Analgesia

Volumn 115, Issue 3, 2012, Pages 713-720

  Wala, Elzbieta P ^a   Crooks, Peter A ^b   McIntosh, J Michael ^c   Holtman, Joseph R ^d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA9ALPHA10; NICOTINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VINCRISTINE; ZZ1 61C;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; GRIP STRENGTH; MALE; MECHANICAL STIMULATION; MOTOR COORDINATION; MOTOR PERFORMANCE; MUSCLE STRENGTH; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; MALE; NEURALGIA; NICOTINIC ANTAGONISTS; PAIN THRESHOLD; PYRIDINIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; VINCRISTINE;

EID: 84865696061     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31825a3c72     Document Type: Article

References (45)

1. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008;13:27-46
2. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008;44:1507-15
3. Arneric SP, Holliday M, Williams M, Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. Biochem Pharmacol 2007;74:1092-101
4. Buccafusco JJ. Neuronal nicotinic receptors subtypes: defining therapeutic targets. Mol Interv 2004;4:285-95
5. O'Hoedt D, Bertrand D. Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin Ther Targets 2009;13:395-411
6. Vincler M. Neuronal nicotinic receptors as targets for novel analgesics. Expert Opin Investig Drugs 2005;14:1191-8
7. Decker MW, Rueter LE, Bitner RS. Nicotinic acetylcholine receptors agonists: a potential new class of analgesics. Curr Top Med Chem 2004;4:369-84
8. Lippello PM, Bencherif TA, Hauser KG, Jordan SR, Letchworth SR, Mazurow AA. Nicotinic receptors as targets for therapeutic discovery. Expert Opin Drug Discov 2007;2:1185-203
9. Lynch JJ, Wade CL, Mikusa JP, Decker MW, Honore P. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model. Eur J Pharmacol 2005;509:43-8
10. Vincler M, McIntosh JM. Targeting theα9α10 nicotinic acetylcholine receptor to treat severe pain. Expert Opin Ther Targets 2007;11:891-7
11. McIntiosh JM, Absalom N, Chebib M, Elgoyhen AB, Vincler M. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. Biochem Pharmacol 2009;78:693-702
12. Satkunanathan N, Livett B, Gayler K, Sandall D, Down J, Khalil Z. Alpha-conotoxin Vc1.1. alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res 2005;1059:149-58
13. Vincler M, Wittenauer S, Parker R, Ellison M, Oliviera BM, McIntosh JM. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 acetylcholine receptors. Proc Natl Acad Sci USA 2006;103:17880-4
14. Ayers JT, Dwoskin LP, Deaciuc AG, Grinevich VP, Zhu J, Crooks PA. Bis-azaaromatic quaternary ammonium analogus; ligands for α4β4 and α7 subtypes of nicotinic receptors. Bioorg Med Chem Lett 2002;12:3067
15. Zhang Z, Zheng G, Pivovarchyk M, Deaciuc AG, Dwoskin LP, Crooks PA. Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that maediate nicotine-evoked dopamine release. Bioorg Med Chem Lett 2008;18:5753-7
16. Zheng G, Sumithran SP, Deaciuc AG, Dwoskin LP, Crooks PA. Tris-azaaromatic quaternary ammonium salts: novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg Med Chem Lett 2007;17:6701-6
17. McIntosh JM, Dwoskin LP, Crooks PA, Holtman JR Jr. GZ5-556A and ZZ2-04G are novel small molecule antagonist ofα9α10 nAChRs and are analgesic in rats. Biochem Pharmacol Suppl 2009;78:921
18. Zheng G, Zhang Z, Dowell C, Wala E, Dwoskin LP, Holtman JR, McIntosh JM, Crooks PA. Discovery of non-peptide, small molecule antagonists ofα9α10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Biorg Med Chem Lett 2011;21:2476-9
19. Holtman JR Jr, Dwoskin LP, Dowell C, Wala EP, Crooks PA, McIntosh JM. Novel small molecule alpha9alpha10 nicotinic receptor antagonists for pain. J Pain Suppl 2010;11:S33
20. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150-61
21. Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-19
22. Bennett G. Pathophysiology and animal models of cancerrelated painful peripheral neuropathies. Oncologists 2010; 15:9-12
23. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anesthesiol 2006;72:151-69
24. Polomano RC, Bennet GJ. Chemotherapy-evoked painful peripheral neuropathy. Pain Med 2001;2:8-14
25. Weng HR, Cordewlla JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompanies vincristineinduced hyperalgesia and allodynia. Pain 2003;103:131-8
26. Flatters SJ, Bennett GJ. Studies on peripheral sensor nerves in paclitaxel-induced painful peripheral neuropathies. Pain 2006;109:150-61
27. Holtman JR Jr, Crooks PA, Johnson-Hardy J, Wala EP. Antinociceptive effects and toxicity of morphine-6-O-sulfate sodium salt in rat. Eur J Pharmacol 2010;648:87-94
28. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001;53:597-652
29. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in human. Neuroscience 1996;73:259-65
30. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. A new animal model of vincristine-induced nociceptive peripheral neuropathy. NeuroToxicology 2003;24:797-805
31. Nozaki-Taguchi N, Chaplan SR, Higuera ES, Ajakwe RC, Yaksh TL. Vincristine-induced allodynia in the rat. Pain 2001;93:69-76
32. Sang CN, Bennett GJ. Novel therapies for the control and prevention of neuropathic pain. Neurotherapeutics 2009;6: 607-8
33. Lynch JJ, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 2004;110:56-63
34. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapyevoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the apha-2-delta type-1 calcium channel subunit. Neuroscience 2007;144:714-20
35. Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG. Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci 2010;67:3017-34
36. Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannbinoid CB1 and CB2 receptors supresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 2007;152:765-77
37. Cata JP, Weng HR, Dougherty PM. Cyclogenase inhibitors and thalidomide ameliorate vincristine-reduced hyperalgesia in rats. Cancer Chemother Pharmacol 2004;54:391-7
38. Pascual D, Goicoechea C, Burgos E, Martin MI. antinocicepotive effect of three common analgesic drugs on peripheral neuropathy by paclitaxel in rats. Pharmacol Biochem Behav 2010;95:331-7
39. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatement of chemotherapy-evoked painful peripheral neuropathies. Pain Med 2008;9:505-17
40. Holtman JR Jr, Crooks PA, Johnson-Hardy J, Wala EP. The analgesic and toxic effects of nornicotine enantiomers alone and in interaction with morphine in rodent models of acute and persistent pain. Pharmacol Biochem Behav 2010;94:352-62
41. Siau C, Bennett GJ. Dysregulation of cellular calcium homeostatsis in chemotherapy-evoked painful peripheral neuropathy. Anesth Analg 2006;102:1485-90
42. Holtman JR Jr, Dwoskin LP, Dowell C, Wala EP, Zhang Z, Crooks PA, McIntosh JM. The novel small moleculeα9α10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. Eur J Pharmacol 2011;670:500-8
43. Clark RJ, Fisher H, Nevin ST, Adams DJ, Craik DJ. The synthesis, structural characterization, and receptor specificity of the α-conotoxin Vc1.1. J Biol Chem 2006;281:23254-63
44. Callaghan B, Haythornthwaite A, Berecki G, Clark RJ, Craik DJ, Adams DJ. Analgesic α-conotoxin Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation. J Neurosci 2008;28:10943-51
45. Nevin ST, Clark RJ, Klimis H, Christe MJ, Clarik DJ, Adams DJ. Areα9α10 nicotinic acetylcholine receptors a pain targets for α-conotoxin. Mol Pharmacol 2007;72:1406-10